4203:TSESumitomo Bakelite Co., Ltd. Analysis
Data as of 2026-03-15 - not real-time
¥5,338.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Sumitomo Bakelite trades at ¥5,338, comfortably above its 20‑day SMA of ¥5,670 and 50‑day SMA of ¥5,467, indicating short‑term price weakness despite a broader bullish trend signaled by the 200‑day SMA at ¥4,884. The RSI sits at 44, suggesting neutral momentum, while the MACD histogram is sharply negative (‑61.9) with a bearish signal, hinting at possible near‑term downside pressure toward the support level of ¥5,078. Volatility remains high at 43% over the past 30 days, though the beta of 0.64 points to lower systematic risk relative to the market. On the valuation side, the DCF‑derived fair value of ¥3,467 is well below the current price, classifying the stock as overvalued despite a modest upside/downside estimate of +13.5% based on analyst targets. The dividend yield of 2.06% with a 42% payout ratio appears sustainable given strong cash balances and free cash flow generation.
Fundamentally, revenue grew 4.3% YoY with a gross margin of 31% and operating margin of 10%, while ROE sits at 8.1% and ROA at 4.3%, reflecting stable but moderate profitability. The balance sheet shows sizable cash (¥120 bn) offset by debt of ¥37.6 bn, yielding a high debt‑to‑equity ratio of 11.3 but manageable leverage due to liquidity. The company’s diversified exposure across semiconductor materials, specialty chemicals, and medical products mitigates sector‑specific shocks, though regulatory and currency considerations remain medium‑level risks.
Fundamentally, revenue grew 4.3% YoY with a gross margin of 31% and operating margin of 10%, while ROE sits at 8.1% and ROA at 4.3%, reflecting stable but moderate profitability. The balance sheet shows sizable cash (¥120 bn) offset by debt of ¥37.6 bn, yielding a high debt‑to‑equity ratio of 11.3 but manageable leverage due to liquidity. The company’s diversified exposure across semiconductor materials, specialty chemicals, and medical products mitigates sector‑specific shocks, though regulatory and currency considerations remain medium‑level risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price trading below short‑term moving averages
- Bearish MACD histogram indicating momentum weakness
- Proximity to support level at ¥5,078
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Overall bullish trend with price above 200‑day SMA
- Upside potential toward resistance at ¥6,063
- Attractive dividend yield and sustainable payout
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Current price exceeds DCF fair value indicating overvaluation
- Steady cash flow generation supporting dividend and operations
- Moderate growth prospects and diversified product portfolio
Key Metrics & Analysis
Financial Health
Revenue Growth4.30%
Profit Margin8.39%
P/E Ratio23.9
ROE8.13%
ROA4.26%
Debt/Equity11.36
P/B Ratio1.4
Op. Cash Flow¥34.5B
Free Cash Flow¥13.5B
Technical Analysis
TrendBullish
RSI43.6
Support¥5,078.00
Resistance¥6,063.00
MA 20¥5,669.70
MA 50¥5,467.38
MA 200¥4,883.87
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair Value¥3,467.39
Target Price¥6,060.00
Upside/Downside13.53%
GradeOvervalued
TypeBlend
Dividend Yield2.06%
Risk Assessment
Beta0.64
Volatility43.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.